about
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceEmerging targeted therapies for melanoma treatment (review)HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.Increased Levels of NF-kB-Dependent Markers in Cancer-Associated Deep Venous Thrombosis.Second primary lymphoma or recurrence: a dilemma solved by VDJ rearrangement analysis.Diabetes mellitus and the risk of bladder cancer: an Italian case–control study.Dietary intakes of carotenoids and other nutrients in the risk of nasopharyngeal carcinoma: a case-control study in ItalyEctopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineStathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.Targeting the leukemic stem cell: the Holy Grail of leukemia therapySuppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.Uterine cervical carcinoma: role of matrix metalloproteinases (review).Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.Emerging Raf inhibitors.Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure.Emerging MEK inhibitors.New perspectives in HCV therapy: entry inhibitors.Understanding rituximab function and resistance: implications for tailored therapy.Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.'Genetic profiling' and ovarian cancer therapy (review).Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).Targeting the cancer initiating cell: the ultimate target for cancer therapy.The tumor microenvironment in hepatocellular carcinoma (review).Breast cancer risk in women treated with augmentation mammoplasty (review).Correlation of the risk of breast cancer and disruption of the circadian rhythm (Review).BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).microRNAs and thyroid cancer: biological and clinical significance (Review).Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy.Targeting breast cancer initiating cells: advances in breast cancer research and therapy.Malignant melanoma in elderly patients: biological, surgical and medical issues.Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis.Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy.
P50
Q24645668-6C32E22C-056A-4FE3-B36B-02B99635778FQ26829997-840AA135-3789-4A9C-9452-2890B1159D16Q33225377-7E89A926-BCE9-44BA-B4ED-5D2DF60CA12CQ34173253-74424CD5-0716-4143-8CA7-86E52C0EDAF8Q34979356-878CC8FD-5B9E-481A-A8A2-F69F880145E4Q35107234-D5300BE8-85FA-416F-9376-B4368DFBD3EAQ35699340-C9FDD416-5FC1-4665-AFB7-80FAD4DA7FD7Q35888674-5DDEB705-3F07-4FA8-AD4C-4044E9F2A46CQ36286678-E849A537-85FB-40EB-9AE9-3DFB93ED1A25Q36385274-B4287457-9086-4739-B07F-E889D0436E38Q36556350-875C7E13-EF68-4FE6-86BD-CB793AB4816CQ36870100-D909644E-F3C0-4699-A073-C9B00A407410Q37109225-0AE3DC48-77DA-4AED-9D39-52A717CBB4B3Q37109227-8CBEAD77-90AC-407B-BF23-2492C8A042A9Q37272565-1A04000F-9FF8-46D6-80A3-71CADD986387Q37331720-FDED2D1E-E7FE-491E-AD77-BC990D5F5162Q37415383-490A4BC7-0790-421A-85DC-163D88174376Q37460101-72181FD9-2B86-4B45-97AE-374526213EBEQ37588717-F8D5DBA6-D68D-41E7-AEA7-C19FA31D9AEBQ37588790-4745D018-C455-4609-BF76-25686FF8D380Q37691441-E4BE2E12-C62C-480C-A485-878A772C0C15Q37760237-9CBA7908-641F-4B82-9C95-8CDA863B3AC5Q37825178-6D8C6B27-DFC8-43F1-A3FF-1036B5BE3D94Q37837732-C5FE88A4-3B42-4B16-9BCA-404B28192A66Q37862111-DEA662A1-3E78-43D5-8EE7-C3239A99230EQ37865381-B465D98E-4E04-46AB-9991-F098D558244EQ37891837-9C569F4B-8B7B-4EBD-8180-0E6B2C70951BQ37971448-144A354B-E50F-41E4-965A-558DC5FBC1A1Q37990970-B9C81402-F59E-411E-A76E-017A2BBE0EFBQ37996920-9D9A2985-C4D0-4B4B-9368-3B4E7D485E9CQ38009258-BDEB5A5D-9F82-4849-977E-330B7C59F052Q38016097-1799E956-5B12-422B-A1D3-1CE9E7D63CC3Q38031762-9A0BAA0B-C694-4087-BAE2-CE3AED984808Q38034913-8DBBA407-D255-4214-9A7A-317C81CDFD5EQ38156313-C87B0C3D-1A74-4B1F-B6B8-E204CCA705B5Q38218970-0F5C1292-30AE-4807-BE0B-7A738A6F7C53Q38253484-90B38515-580A-4448-BEA3-DE48EE2E56A6Q38276802-0B57FD54-73A8-4182-B602-8A46A4BB194DQ38563570-2CAC475E-DB0E-40A6-AD2A-08743091D54DQ38567634-966680FE-7F36-4D5C-8863-112C1C49F9AA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Massimo Libra
@ast
Massimo Libra
@en
Massimo Libra
@es
Massimo Libra
@nl
Massimo Libra
@sl
type
label
Massimo Libra
@ast
Massimo Libra
@en
Massimo Libra
@es
Massimo Libra
@nl
Massimo Libra
@sl
prefLabel
Massimo Libra
@ast
Massimo Libra
@en
Massimo Libra
@es
Massimo Libra
@nl
Massimo Libra
@sl
P106
P1153
6603852432
P21
P31
P496
0000-0002-7232-7737